China's Ausia BioTech seeks international pharma customers

By Gareth Macdonald

- Last updated on GMT

Pictorial representation of Marco Polo's journey from 1375
Pictorial representation of Marco Polo's journey from 1375
Hangzhou CMO Ausia BioTech has partnered with New Mexico-based PaizaBio to market its manufacturing services to Western drugmakers interested in the Chinese sterile injectables market. 

The Chinese contractor called on newly founded PaizaBio to help market its services to international drug firms in June. The first stage of this campaign - announced today - is to try to win business from companies attracted by but wary of the Chinese market.

Ausia BioTech operates a 40,000 square meter site in Hangzhou that houses an analysis laboratory, manufacturing capacity and warehousing space. The contract manufacturing organisation (CMO) also has a “sterile university” that provides training for operatives who work in aseptic production environments.

PaizaBio – which is due to be launched officially at a tradeshow in Spain next month – is a much smaller operation.

The firm – which is named after the paiza medallion apparently presented to Marco Polo by Chinese Emperor Kublai Khan – is based at Albuquerque’s Bioscience Center and employs a three-strong team of pharma industry experts and marketers.

The plan is the Ausia BioTech will either provide Western firms with contract manufacturing services for products for the Chinese market or allow them to test the market before building their own production facilities.

PaizaBio founder Stuart Rose described the firm as a “safe ‘portal’ to the Chinese sterile injectables drug market for Western pharmaceutical companies​.”

He added that: “Our clients will enjoy rapid entry in the Chinese market with no significant capital outlay, and with a partner that provides manufacturing innovation and quality products that meet China’s regulations, in the formats and packaging the market prefers​.”

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers